Wilson Trevor T, Waters Lorraine, Patterson Chris C, McCusker Chris G, Rooney Nichola M, Marlow Neil, Halliday Henry L
Regional Neonatal Unit, Royal Maternity Hospital, Belfast BT12 6BB, Northern Ireland.
Pediatrics. 2006 Jun;117(6):2196-205. doi: 10.1542/peds.2005-2194.
The goals were to compare early school-age neurodevelopmental and respiratory outcomes for children who were treated with either early (<3 days) or delayed selective (>15 days) postnatal corticosteroid therapy and to compare systemic dexamethasone treatment with inhaled budesonide treatment.
One hundred twenty-seven (84%) of 152 survivors from the United Kingdom and Ireland who were recruited to the Open Study of Early Corticosteroid Treatment, a randomized trial of inhaled and systemic corticosteroid therapy to prevent chronic lung disease, were traced and assessed at a median age of 7 years. Outcome measures were level of disability, presence of cerebral palsy, cognitive ability, behavioral difficulties and competencies, growth, and respiratory symptoms. Results were adjusted for potential confounding variables (gestational age, birth weight, gender, prenatal steroid therapy, method of delivery, Apgar score at 5 minutes, and Clinical Risk Index for Babies score).
There were no significant differences among the treatment groups in cognitive ability, behavioral competencies or difficulties, overall disability rates, cerebral palsy, combined outcomes of death or cerebral palsy and death or moderate/severe disability, growth, respiratory morbidity, or diastolic blood pressure. Those assigned to dexamethasone were more likely to have high systolic blood pressure and to have a diagnosis of asthma than were those assigned to budesonide.
Although postnatal steroid therapy has been associated with poor long-term outcomes, this study failed to show significant differences in cognitive function between dexamethasone- and budesonide-allocated groups. There may be increased systolic blood pressure and a greater likelihood of developing asthma in childhood after postnatal dexamethasone treatment.
比较接受早期(<3天)或延迟选择性(>15天)产后皮质类固醇治疗的儿童的早期学龄期神经发育和呼吸结局,并比较全身地塞米松治疗与吸入布地奈德治疗。
从英国和爱尔兰招募到早期皮质类固醇治疗开放研究中的152名幸存者中的127名(84%),该研究是一项吸入和全身皮质类固醇治疗预防慢性肺病的随机试验,在这些儿童7岁时进行追踪和评估。结局指标包括残疾程度、脑瘫的存在、认知能力、行为困难和能力、生长情况以及呼吸道症状。对结果进行了潜在混杂变量(胎龄、出生体重、性别、产前类固醇治疗、分娩方式、5分钟时的阿氏评分以及婴儿临床风险指数评分)的校正。
治疗组在认知能力、行为能力或困难、总体残疾率、脑瘫、死亡或脑瘫以及死亡或中度/重度残疾的综合结局、生长、呼吸道发病率或舒张压方面没有显著差异。与分配到布地奈德的儿童相比,分配到地塞米松的儿童更有可能出现高收缩压并被诊断为哮喘。
尽管产后类固醇治疗与不良的长期结局相关,但本研究未能显示地塞米松组和布地奈德组在认知功能上有显著差异。产后地塞米松治疗后儿童期可能会出现收缩压升高和患哮喘的可能性增加。